Abiprubart is under clinical development by Kiniksa Pharmaceuticals and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II drugs for Rheumatoid Arthritis have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Abiprubart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Abiprubart overview

Abiprubart is under development for the treatment of rheumatoid arthritis. It is administered through intravenous or subcutaneous route. The drug candidate is a monoclonal antibody. It acts by targeting CD40 ligand.

It was also under development for the treatment of focal segmental glomerulosclerosis (FSGS), autoimmune diseases including T-cell-dependent, B-cell-mediated diseases, such as pemphigus/pemphigoid, myasthenia gravis, or graft versus host disease, sicca syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative colitis, lupus nephritis, hidradenitis suppurativa, transplant rejection of heart, pancreatic islet and kidney, idiopathic thrombocytopenic purpura. 

Kiniksa Pharmaceuticals overview

Kiniksa Pharmaceuticals (Kiniksa) is a biopharmaceutical company that discovers, acquires, develops and commercializes medicines to treat autoinflammatory and autoimmune diseases. The company’s pipeline product portfolio includes Rilonacept drug for the treatment of recurrent pericarditis; mavrilimumab, against giant cell arteritis, COVID-19 and hyper inflammation; vixarelimab, targeting prurigo nodularis and diseases characterized by chronic pruritus; KPL-404, a monoclonal antibody to treat T-cell dependent, B-Cell–mediated indications. It develops medicines in the therapeutic areas of cardiovascular, dermatology and autoimmune diseases. The company operates in Bermuda, the US and the UK. Kiniksa is headquartered in Hamilton, Bermuda.

For a complete picture of Abiprubart’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.